Merck to Acquire Caraway Therapeutics, Inc.

Merck, known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to $610 million, including an undisclosed upfront payment as well as contingent milestone payments. Read more.